KR100616020B1 - 맥관장애및이종이식술에서의라파마이신유도체의용도 - Google Patents
맥관장애및이종이식술에서의라파마이신유도체의용도 Download PDFInfo
- Publication number
- KR100616020B1 KR100616020B1 KR1019980707662A KR19980707662A KR100616020B1 KR 100616020 B1 KR100616020 B1 KR 100616020B1 KR 1019980707662 A KR1019980707662 A KR 1019980707662A KR 19980707662 A KR19980707662 A KR 19980707662A KR 100616020 B1 KR100616020 B1 KR 100616020B1
- Authority
- KR
- South Korea
- Prior art keywords
- rapamycin
- formula
- compound
- vascular
- rejection
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
- 활성 성분으로서의 40-O-(2-히드록시에틸)-라파마이신과 제약학적으로 허용가능한 그의 희석제 또는 담체 1종 이상을 포함하는, 신혈관내막 증식 및 비후화를 예방 또는 치료하기 위한 약제 조성물.
- 제1항에 있어서, 활성 성분으로서의 40-O-(2-히드록시에틸)-라파마이신과 제약학적으로 허용가능한 그의 희석제 또는 담체 1종 이상을 포함하는, 혈관 손상에 따른 재발협착증 및(또는) 혈관 폐색을 예방 또는 치료하기 위한 약제 조성물.
- 제1항에 있어서, 활성 성분으로서의 40-O-(2-히드록시에틸)-라파마이신과 제약학적으로 허용가능한 그의 희석제 또는 담체 1종 이상을 포함하는, 장기 또는 조직 동종이식편의 피이식자에게서 이식편 혈관 질환을 예방 또는 치료하기 위한 약제 조성물.
- 제1항에 있어서, 시클로스포린 (cyclosporin) A, FK-506, 아자타이오프린 (azathioprine), 메토트렉세이트 (methotrexate), 마이코페놀산 (mycophenolic acid), 마이코페놀레이트 모페틸 (mycophenolate mofetil), 15-디옥시스페르구알린 (15-deoxyspergualine) 또는 백혈구 수용체나 그의 리간드에 대한 단클론성 항체와 조합하여 사용하는 조성물.
- 제4항에 있어서, 상기 단클론성 항체가 MHC, CD2, CD3, CD4, CD7, CD25, CD28, B7, CD45 또는 CD58 또는 그의 리간드에 대한 단클론성 항체인 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019980707662A KR100616020B1 (ko) | 1996-03-27 | 1997-03-26 | 맥관장애및이종이식술에서의라파마이신유도체의용도 |
KR1020057005463A KR100836971B1 (ko) | 1996-03-27 | 1997-03-26 | 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9606452.2 | 1996-03-27 | ||
KR1019980707662A KR100616020B1 (ko) | 1996-03-27 | 1997-03-26 | 맥관장애및이종이식술에서의라파마이신유도체의용도 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057005463A Division KR100836971B1 (ko) | 1996-03-27 | 1997-03-26 | 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20000005038A KR20000005038A (ko) | 2000-01-25 |
KR100616020B1 true KR100616020B1 (ko) | 2007-01-31 |
Family
ID=41611582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019980707662A KR100616020B1 (ko) | 1996-03-27 | 1997-03-26 | 맥관장애및이종이식술에서의라파마이신유도체의용도 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100616020B1 (ko) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0551182A1 (en) * | 1992-01-09 | 1993-07-14 | American Home Products Corporation | Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid |
WO1994009010A1 (en) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
-
1997
- 1997-03-26 KR KR1019980707662A patent/KR100616020B1/ko not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0551182A1 (en) * | 1992-01-09 | 1993-07-14 | American Home Products Corporation | Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid |
WO1994009010A1 (en) * | 1992-10-09 | 1994-04-28 | Sandoz Ltd. | O-alkylated rapamycin derivatives and their use, particularly as immunosuppressants |
Non-Patent Citations (1)
Title |
---|
Transplantation, 55(6), June 1993, Clare R. Gregory et al., ''Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury'', 1409-1418 * |
Also Published As
Publication number | Publication date |
---|---|
KR20000005038A (ko) | 2000-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100836971B1 (ko) | 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도 | |
JP2009102349A6 (ja) | 血管疾病および異種移植におけるラパマイシン誘導体の使用 | |
RU2217136C2 (ru) | Новое применение 1,3-пропандиольных производных | |
US20030232867A1 (en) | Use | |
EP1567138B1 (en) | Use of a diamide derivative for inhibiting chronic transplant rejection | |
JP2002541195A (ja) | 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物 | |
KR100616020B1 (ko) | 맥관장애및이종이식술에서의라파마이신유도체의용도 | |
WO1997042953A1 (en) | Use of brequinar and derivatives in chronic rejection of allografts and xenotransplantation | |
TW550074B (en) | Pharmaceutical composition for preventing or treating vasculopathies and chronic rejection | |
JP3720400B2 (ja) | 免疫拒絶反応抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
A107 | Divisional application of patent | ||
AMND | Amendment | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20050228 Effective date: 20060427 |
|
S901 | Examination by remand of revocation | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20120727 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20130723 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140722 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150717 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160720 Year of fee payment: 11 |
|
EXPY | Expiration of term |